NEW YORK, Feb. 7 /PRNewswire/ -- JDS Pharmaceuticals, L.L.C. and Synthon Pharmaceuticals, Ltd. today announced that they have entered into a co-promotion agreement for LITHOBID(R) (lithium carbonate), a leading brand of twice daily lithium carbonate for the treatment of bipolar disorder.
Synthon will co-promote LITHOBID through its sales force of approximately 50 sales representatives to high volume prescribing psychiatrists. Financial terms of the agreement were not disclosed.
"We believe LITHOBID is an important option in the treatment of bipolar disorder," said Phillip M. Satow, Chairman and Chief Executive Officer of JDS. "The Synthon sales force will provide a unique opportunity to expand LITHOBID prescribing by thousands of psychiatrists across the country."
"We are enthusiastic about our agreement with Synthon, as it provides significant benefit for both companies," said Mr. Satow. "For JDS, it is a milestone as we establish ourselves for both near and long-term growth in revenue."
Andrew Shales, Vice President of Sales and Marketing for Synthon said, "We are very excited about the addition of LITHOBID to our portfolio, as it represents an excellent strategic fit for us. It is a very significant addition to our specialty branded business and will further strengthen our U.S. market presence."
Bipolar Disorder Background
Bipolar disorder, also known as manic-depressive illness, affects an individual's mood, behavior and thinking. More than 2.5 million Americans live with a diagnosis of bipolar disorder, but it has been reported that the number may be as high as 10 million. The results of untreated bipolar disorder have severe consequences. An estimated 25 percent of patients with bipolar disorder attempt suicide at least once and approximately 20 percent actually succeed. This is one of the highest rates for any psychiatric disorder and three times higher than that of the general population. The World Health Organization estimates that bipolar disorder is the sixth leading cause of disability in the world.
LITHOBID is indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania.
Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy.
Common side effects of LITHOBID Slow-Release Tablets during initial therapy include fine hand tremor, polyuria, mild thirst, and transient and mild nausea. These side effects usually subside with continued treatment, temporary reduction of dosage, or cessation of therapy.
Patients with severe cardiovascular or renal diseases and those with evidence of severe debilitation or dehydration, sodium depletion or brain damage should not use this product.
About JDS Pharmaceuticals, L.L.C.
JDS Pharmaceuticals, L.L.C. is a New York-based specialty pharmaceutical company created to sell, market and develop proprietary and branded pharmaceutical products in niche therapeutic markets. Execution of the Company's strategy will involve the acquisition of underperforming products that can be reinvigorated as well as the continued creation of a sales, marketing, and business development infrastructure that will attract new opportunities. Information on JDS Pharmaceuticals L.L.C. can be viewed at http://www.jdspharma.com/.
About Synthon Pharmaceuticals
The Synthon family of companies discovers, develops and markets both active pharmaceutical ingredients and finished pharmaceutical dosage forms. The companies market a broad therapeutic portfolio of 56 products in more than 38 countries around the world. The Synthon family of companies is renowned for successful drug discovery, quality products, excellent drug submissions, innovative analysis and quality control testing. Information on Synthon Pharmaceuticals Ltd. can be viewed at http://www.synthon-usa.com/.
JDS Pharmaceuticals, L.L.C.